Immune Regulation Ltd., a U.S.-U.K. venture advancing peptide-based therapies for rheumatoid arthritis and allergic diseases, has closed a £40.6 million (US$53.4 million) series B financing that will support its preparation for multiple phase II studies next year, as well as an evaluation of one candidate in COVID-19-related acute respiratory distress syndrome. Morningside Ventures led the round, along with existing shareholders, including London-based 24Haymarket.

Outset Medical Inc. closed its Nasdaq IPO Thursday with gross proceeds of approximately of $277.9 million. The IPO, which launched Tuesday, included nearly 10.3 million shares of common stock at $27 per share and the full exercise of underwriters’ option to purchase more than 1.3 million additional shares. Shares of the San Jose, Calif.-based company’s stock, which is trading under the ticker OM, soared to more than $60 on the first day of trading amid enthusiasm for its portable dialysis machine.

LONDON – Sleep disorder specialist Nyxoah SA hit the top end of its price range of €17 per share, raising €84.75 million (US$100) million in its initial public offering. Assuming full exercise of the over-allotment option, the company will have a market capitalization of €375.26 million. The shares began trading on Euronext Brussels (EBR:NYXH) on Sept. 18, and had a good first day, closing up 14.7%, at €19.50.

Upsized IPOs for high-profile psychedelics venture Compass Pathways plc and the neurodegenerative specialist Athira Pharma Inc. debuted on Nasdaq on Sept. 18, climbing fast alongside a forward-looking follow-on offering from cytokine storm fighter Humanigen Inc. Compass (NASDAQ:CMPS) raised $127.5 million, while Athira (NASDAQ:ATHA) brought in $204 million. Humanigen (NASDAQ:HGEN) raised $68 million.